Cargando…

Survival outcomes in node-positive non-metastatic bladder cancer: An analysis of the national cancer database

INTRODUCTION: Clinically node-positive non-metastatic bladder cancer (cN+) has been the target of several studies aiming to establish a standard of care for this population. Limited studies have shown a survival benefit for various multimodal therapy approaches. The role of radiation therapy has not...

Descripción completa

Detalles Bibliográficos
Autores principales: Elbakry, Amr A, Trump, Tyler, Ferari, Christopher, Mattes, Malcom D, Luchey, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639493/
https://www.ncbi.nlm.nih.gov/pubmed/36353472
http://dx.doi.org/10.1080/2090598X.2022.2077001
_version_ 1784825652650704896
author Elbakry, Amr A
Trump, Tyler
Ferari, Christopher
Mattes, Malcom D
Luchey, Adam
author_facet Elbakry, Amr A
Trump, Tyler
Ferari, Christopher
Mattes, Malcom D
Luchey, Adam
author_sort Elbakry, Amr A
collection PubMed
description INTRODUCTION: Clinically node-positive non-metastatic bladder cancer (cN+) has been the target of several studies aiming to establish a standard of care for this population. Limited studies have shown a survival benefit for various multimodal therapy approaches. The role of radiation therapy has not been well established. Our study aims to study the trends of the reported treatment options offered to patients with cN+ bladder cancer in a national database and to evaluate the effect of various treatments, including radiation, on survival. METHODS: The National Cancer Database (NCDB) was used to identify cN+ bladder cancer patients who received chemotherapy alone or in combination with radical cystectomy (RC) or radiotherapy. 3,481 patients were included and divided into 4 groups: chemotherapy only, chemotherapy and RC, chemotherapy and radiation therapy, and chemotherapy, RC, and radiation therapy. Demographic data was compared using ANOVA for continuous variables, and Chi-square for categorical variables. Multivariable analysis was done to compare groups using a multinomial logistic regression model. Kaplan-Meier test was used for survival analysis and Cox-Regression was used for multivariable survival analysis. RESULTS: Patients undergoing RC were significantly younger (P <0.001). There was a significant difference between the groups regarding racial distribution, facility-type and insurance status. There was no difference in gender, Charlson\Deyo score, financial or educational status. Patients who underwent combination therapy with chemotherapy and RC were found to have the longest median survival time at 27 months. Multivariable analysis showed that final treatment, age, sex, Charlson\Deyo comorbidity score, TNM edition and facility-type were significant survival predictors. Race, insurance and financial status failed to maintain significance. There was no survival difference between the chemotherapy group and chemo-radiotherapy group. CONCLUSIONS: The combination of surgery and chemotherapy achieves statistically significant superior survival in cN+ bladder cancer. Adding radiotherapy to chemotherapy did not improve survival in this group of patients. ABBREVIATIONS: (cN+): Clinically node-positive non-metastatic, (MIBC): Muscle invasive bladder cancer, (NCDB): National Cancer Database, (NAC): Neoadjuvant chemotherapy, (RC): Radical Cystectomy
format Online
Article
Text
id pubmed-9639493
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-96394932022-11-08 Survival outcomes in node-positive non-metastatic bladder cancer: An analysis of the national cancer database Elbakry, Amr A Trump, Tyler Ferari, Christopher Mattes, Malcom D Luchey, Adam Arab J Urol Oncology/Reconstruction INTRODUCTION: Clinically node-positive non-metastatic bladder cancer (cN+) has been the target of several studies aiming to establish a standard of care for this population. Limited studies have shown a survival benefit for various multimodal therapy approaches. The role of radiation therapy has not been well established. Our study aims to study the trends of the reported treatment options offered to patients with cN+ bladder cancer in a national database and to evaluate the effect of various treatments, including radiation, on survival. METHODS: The National Cancer Database (NCDB) was used to identify cN+ bladder cancer patients who received chemotherapy alone or in combination with radical cystectomy (RC) or radiotherapy. 3,481 patients were included and divided into 4 groups: chemotherapy only, chemotherapy and RC, chemotherapy and radiation therapy, and chemotherapy, RC, and radiation therapy. Demographic data was compared using ANOVA for continuous variables, and Chi-square for categorical variables. Multivariable analysis was done to compare groups using a multinomial logistic regression model. Kaplan-Meier test was used for survival analysis and Cox-Regression was used for multivariable survival analysis. RESULTS: Patients undergoing RC were significantly younger (P <0.001). There was a significant difference between the groups regarding racial distribution, facility-type and insurance status. There was no difference in gender, Charlson\Deyo score, financial or educational status. Patients who underwent combination therapy with chemotherapy and RC were found to have the longest median survival time at 27 months. Multivariable analysis showed that final treatment, age, sex, Charlson\Deyo comorbidity score, TNM edition and facility-type were significant survival predictors. Race, insurance and financial status failed to maintain significance. There was no survival difference between the chemotherapy group and chemo-radiotherapy group. CONCLUSIONS: The combination of surgery and chemotherapy achieves statistically significant superior survival in cN+ bladder cancer. Adding radiotherapy to chemotherapy did not improve survival in this group of patients. ABBREVIATIONS: (cN+): Clinically node-positive non-metastatic, (MIBC): Muscle invasive bladder cancer, (NCDB): National Cancer Database, (NAC): Neoadjuvant chemotherapy, (RC): Radical Cystectomy Taylor & Francis 2022-05-20 /pmc/articles/PMC9639493/ /pubmed/36353472 http://dx.doi.org/10.1080/2090598X.2022.2077001 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Oncology/Reconstruction
Elbakry, Amr A
Trump, Tyler
Ferari, Christopher
Mattes, Malcom D
Luchey, Adam
Survival outcomes in node-positive non-metastatic bladder cancer: An analysis of the national cancer database
title Survival outcomes in node-positive non-metastatic bladder cancer: An analysis of the national cancer database
title_full Survival outcomes in node-positive non-metastatic bladder cancer: An analysis of the national cancer database
title_fullStr Survival outcomes in node-positive non-metastatic bladder cancer: An analysis of the national cancer database
title_full_unstemmed Survival outcomes in node-positive non-metastatic bladder cancer: An analysis of the national cancer database
title_short Survival outcomes in node-positive non-metastatic bladder cancer: An analysis of the national cancer database
title_sort survival outcomes in node-positive non-metastatic bladder cancer: an analysis of the national cancer database
topic Oncology/Reconstruction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639493/
https://www.ncbi.nlm.nih.gov/pubmed/36353472
http://dx.doi.org/10.1080/2090598X.2022.2077001
work_keys_str_mv AT elbakryamra survivaloutcomesinnodepositivenonmetastaticbladdercancerananalysisofthenationalcancerdatabase
AT trumptyler survivaloutcomesinnodepositivenonmetastaticbladdercancerananalysisofthenationalcancerdatabase
AT ferarichristopher survivaloutcomesinnodepositivenonmetastaticbladdercancerananalysisofthenationalcancerdatabase
AT mattesmalcomd survivaloutcomesinnodepositivenonmetastaticbladdercancerananalysisofthenationalcancerdatabase
AT lucheyadam survivaloutcomesinnodepositivenonmetastaticbladdercancerananalysisofthenationalcancerdatabase